Neurogene shares last traded at $33.1840, with a volume of 5,144 shares changing hands. Wall Street Analysts Forecast GrowthSeveral research analysts have recently issued reports on NGNE shares. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research report on Tuesday, June 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. Over the last 90 days, insiders sold 19,200 shares of company stock worth $639,932.